Identification of Biomarkers Associated With Pathological Stage and Prognosis of Clear Cell Renal Cell Carcinoma by Co-expression Network Analysis

Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer whose prognostic is affected by the tumor progression associated with complex gene interactions. However, there is currently no available molecular markers associated with ccRCC progression and used or clinical application. In our study, microarray data of 101 ccRCC samples and 95 normal kidney samples were analyzed and 2,425 differentially expressed genes (DEGs) were screened. Weighted gene co-expression network analysis (WGCNA) was then conducted and 11 co-expressed gene modules were identified. Module preservation analysis revealed that two modules (red and black) were found to be most stable. In addition, Pearson's correlation analysis identified the module most relevant to pathological stage(patho-module) (r = 0.44, p = 3e-07). Functional enrichment analysis showed that biological processes of the patho-module focused on cell cycle and cell division related biological process and pathway. In addition, 29 network hub genes highly related to ccRCC progression were identified from the stage module. These 29 hub genes were subsequently validated using 2 other independent datasets including GSE53757 (n = 72) and TCGA (n = 530), and the results indicated that all hub genes were significantly positive correlated with the 4 stages of ccRCC progression. Kaplan-Meier survival curve showed that patients with higher expression of each hub gene had significantly lower overall survival rate and disease-free survival rate, indicating that all hub genes could act as prognosis and recurrence/progression biomarkers of ccRCC. In summary, we identified 29 molecular markers correlated with different pathological stages of ccRCC. They may have important clinical implications for improving risk stratification, therapeutic decision and prognosis prediction in ccRCC patients.

[1]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Xinghuan Wang,et al.  Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma , 2017, International journal of biological sciences.

[3]  Pengfei Chen,et al.  Co-expression network analysis identified six hub genes in association with metastasis risk and prognosis in hepatocellular carcinoma , 2017, Oncotarget.

[4]  Yunfeng Zhou,et al.  Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis , 2017, Oncotarget.

[5]  B. Dai,et al.  Identification and validation of an eight‐gene expression signature for predicting high Fuhrman grade renal cell carcinoma , 2017, International journal of cancer.

[6]  A. Belldegrun,et al.  Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma , 2016, Scientific Reports.

[7]  Wenquan Zhou,et al.  Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas. , 2015, International journal of clinical and experimental pathology.

[8]  Haifei Xu,et al.  Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas. , 2015, International journal of clinical and experimental pathology.

[9]  S. Horvath,et al.  Single-Cell Transcriptome Analyses Reveal Signals to Activate Dormant Neural Stem Cells , 2015, Cell.

[10]  J. Choudhary,et al.  Identification of protein complexes that bind to histone H3 combinatorial modifications using super-SILAC and weighted correlation network analysis , 2015, Nucleic acids research.

[11]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[12]  D. Radisky,et al.  Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. , 2014, Cancer research.

[13]  Chun-Yu Chuang,et al.  Visual gene-network analysis reveals the cancer gene co-expression in human endometrial cancer , 2014, BMC Genomics.

[14]  S. Cha,et al.  VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma , 2014, Journal of lifestyle medicine.

[15]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[16]  L. O’Driscoll,et al.  Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. , 2013, Carcinogenesis.

[17]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[18]  T. Wilt,et al.  Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials , 2011, BJU international.

[19]  Rui Luo,et al.  Is My Network Module Preserved and Reproducible? , 2011, PLoS Comput. Biol..

[20]  C. Farber Identification of a gene module associated with BMD through the integration of network analysis and genome‐wide association data , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Goel,et al.  Understanding survival analysis: Kaplan-Meier estimate , 2010, International journal of Ayurveda research.

[22]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[23]  C. Porta,et al.  Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. , 2010, European journal of cancer.

[24]  S. Horvath,et al.  Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways , 2010, Proceedings of the National Academy of Sciences.

[25]  P. Bühlmann,et al.  Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer , 2009, Clinical Cancer Research.

[26]  Steve Horvath,et al.  A Systems Genetics Approach Implicates USF1, FADS3, and Other Causal Candidate Genes for Familial Combined Hyperlipidemia , 2009, PLoS genetics.

[27]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[28]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[29]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[30]  G. Church,et al.  Systematic determination of genetic network architecture , 1999, Nature Genetics.

[31]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[32]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[33]  S. Hancock,et al.  Kidney cancer, version 3.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  P. Cairns Renal cell carcinoma. , 2010, Cancer biomarkers : section A of Disease markers.

[35]  A. Ravaud,et al.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.

[36]  Xianrang Song,et al.  Maturation of a central , 1996 .

[37]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[38]  John D. Storey,et al.  Supplementary Text: Capturing Heterogeneity in Gene Expression Studies Nested Ks-tests: a Procedure to Test Whether a Procedure Is Valid , 2022 .